In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: A cross-sectional study

Transplantation Proceedings

Volumn 43, Issue 8, 2011, Pages 3071-3073

  Zakliczynski, M ^a   Boguslawska, J ^a   Wojniak, E ^a   Zakliczynska, H ^a   Ciesla, D ^a   Nozynski, J ^a   Szygula Jurkiewicz, B ^a   Zeglen, S ^a   Zembala, M ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; EVEROLIMUS; EZETIMIBE; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; CARDIAC ALLOGRAFT CORONARY VASCULOPATHY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 80054758165     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.08.052     Document Type: Conference Paper

References (13)

1. J.A. Kobashigawa, S. Katznelson, and H. Laks Effect of pravastatin on outcomes after cardiac transplantation N Engl J Med 333 1995 621
2. M.R. Mehra, P.A. Uber, and K. Vivekananthan Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival J Am Coll Cardiol 40 2002 1609
3. K. Wenke, B. Meiser, and J. Thiery Simvastatin initiated early after heart transplantation: 8-year prospective experience Circulation 107 2003 93
4. M.R. Mehra, and N.Y. Raval Metaanalysis of statins and survival in de novo cardiac transplantation Transplant Proc 36 2004 1539
5. W.T. Mahle, R.N. Vincent, and A.M. Berg Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation J Heart Lung Transplant 24 2005 63
6. J.A. Kobashigawa, J.D. Moriguchi, and H. Laks Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients J Heart Lung Transplant 24 2005 1736
7. M.R. Costanzo, A. Dipchand, and R. Starling The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients J Heart Lung Transplant 29 2010 914
8. H.J. Eisen, E.M. Tuzcu, and R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847
9. A. Keogh, M. Richardson, and P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial Circulation 110 2004 2694
10. M.R. Mehra Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy Am J Transplant 6 2006 1248
11. J.A. Kobashigawa, R.C. Starling, and M.R. Mehra Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients J Heart Lung Transplant 25 2006 1063
12. A.K. Khanna, J. Xu, and P.A. Uber Tobacco smoke exposure in either the donor or recipient before transplantation accelerates cardiac allograft rejection, vascular inflammation, and graft loss Circulation 120 2009 1814
13. B.F. Vandenberg, and J. Robinson Management of the patient with statin intolerance Curr Atheroscler Rep 12 2010 48